The quarter was a modest EPS beat, not a broad upside surprise. Comparable EPS reached $4.07 versus the published consensus of roughly $4.02, while revenue of $1.217 billion was approximately in line with the roughly $1.22 billion expectation.
| Metric | Q2 2026 | Prior year / expectation |
|---|---|---|
| Revenue | $1.217B (Income Statement) | $1.109B prior year; ~$1.22B consensus |
| Comparable EPS | $4.07 (EPS reconciliation) | $3.53 prior year; ~$4.02 consensus |
| Comparable operating margin | 34.7% (Financial Highlights) | 33.6% prior year |
| Organic revenue growth | 9.0% (Revenue growth tables) | 8.5% midpoint of updated FY guidance |
Underlying recurring revenue remained the main engine. CAG Diagnostics recurring revenue grew 10% organically, with IDEXX VetLab consumables up 14% and reference laboratory services up 10%; that offset a 20% organic decline in capital instrument revenue as the company lapped last year's inVue Dx rollout. (CAG revenue tables)
Profitability was better than the headline growth rate suggests. Comparable operating margin expanded 110 basis points to 34.7%, supported by recurring-revenue mix, productivity, and pricing; comparable operating profit grew 12%, ahead of comparable revenue growth of 9%. (Financial Highlights)
Management raised the full-year framework, giving the report its clearest incremental signal. Revenue guidance moved to $4.700-$4.745 billion from $4.675-$4.760 billion, lifting the midpoint by $5 million despite a $15 million foreign-exchange headwind. Organic-growth guidance rose to 8.5%-9.7% from 7.7%-9.7%, while the operating-margin range increased to 32.3%-32.5% from 32.1%-32.5% and EPS to $14.69-$14.94 from $14.45-$14.90. (2026 Growth and Financial Performance Outlook)
Net: narrowly better than expected, with quality improving through recurring revenue and margins. The revenue result itself was not a meaningful beat, and capital instruments remain weak, but the EPS outperformance plus higher organic-growth, margin, and EPS outlooks make this more than an in-line quarter.
Read the original 8-K on SEC EDGAR ↗